Integra LifeSciences delivered a first quarter that surpassed Wall Street expectations, as reflected by a significant positive market reaction. Management attributed the results to stronger demand for tissue reconstruction products, improved supply execution, and ongoing transformation initiatives. CEO Stuart Essig, newly reinstated, emphasized that foundational work in quality remediation and operational improvements enabled more reliable product availability. CFO Lea Knight highlighted that increased gross margins were “driven by a favorable product mix, tariff benefits, and reduced remediation costs,” indicating that operational discipline and targeted initiatives were key contributors to the quarter’s performance.
Is now the time to buy IART? Find out in our full research report (it’s free for active Edge members).
Integra LifeSciences (IART) Q1 CY2026 Highlights:
- Revenue: $391.9 million vs analyst estimates of $381.9 million (2.4% year-on-year growth, 2.6% beat)
- Adjusted EPS: $0.54 vs analyst estimates of $0.40 (33.4% beat)
- Adjusted EBITDA: $76.18 million vs analyst estimates of $66.65 million (19.4% margin, 14.3% beat)
- The company reconfirmed its revenue guidance for the full year of $1.68 billion at the midpoint
- Management raised its full-year Adjusted EPS guidance to $2.45 at the midpoint, a 4.3% increase
- Operating Margin: 10.4%, up from 8.2% in the same quarter last year
- Organic Revenue rose 1.3% year on year (beat)
- Market Capitalization: $1.09 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Integra LifeSciences’s Q1 Earnings Call
-
Matthew Taylor (Jefferies) asked why now was the right time for the CEO transition and how future execution would differ. CEO Stuart Essig stressed continuity of strategic initiatives and a renewed commercial focus.
-
Jayson Bedford (Raymond James & Associates) questioned the status of the Compliance Master Plan and product availability. CFO Lea Knight explained that remediation is progressing, and supply improvements have already enhanced Q1 execution, but no major product returns are assumed in guidance.
-
Ryan Zimmerman (BTIG) inquired about portfolio optimization and market focus. Essig stated there are no plans for divestitures or market exits, emphasizing confidence in the current product mix and niche market positioning.
-
Ross Osborn (Wells Fargo) sought clarification on revenue guidance and adoption of the CUSA product. Knight pointed to strong demand in neurosurgery and highlighted that the company is maintaining a prudent approach to full-year guidance.
-
K. Gong (JPMorgan) asked about expectations for recapturing market share with product relaunches. Knight noted that guidance does not require significant contributions from returning products in 2026, and share recovery is expected to be gradual.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will monitor (1) the ramp-up of production at the Braintree facility and the successful relaunch of SurgiMend, (2) ongoing supply reliability and the company’s ability to maintain product availability, and (3) the impact of Medicare reimbursement changes on both inpatient and outpatient wound care revenue. Progress in these areas will serve as indicators of Integra LifeSciences’ ability to sustain growth and margin improvement.
Integra LifeSciences currently trades at $13.96, up from $10.65 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
